| Name | Title | Contact Details |
|---|
Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD). We use advanced machine learning and computer vision to interpret endoscopic images along with other types of data, helping clinicians to better assess patients with potential GI problems. This gives practitioners enhanced capabilities in the detection, annotation, disease scoring and treatment of GI related diseases. Iterative Health is initially applying these advances towards standardizing disease severity characterization for inflammatory bowel disease. Ultimately, the company aims to establish more meaningful endpoints to serve as better predictors of both therapeutic response and disease outcomes. The company is headquartered in Cambridge, Massachusetts.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Confluence Health is an integrated, rural healthcare delivery system with two hospitals, multi-specialty care in more than 30 service lines and primary care in 12 communities across North Central Washington. Our 250+ physicians and 150+ advanced practice clinicians serve an area of approximately 12,000 square miles and cover nearly every corner of the region through specialty outreach. Confluence Health is dedicated to improving our patients` health by providing safe, high-quality care in a compassionate and cost-effective manner. Core Values • Our patients are the reason for our being, and their needs will drive all of our actions. • We will treat everyone with dignity,respect and compassion. • We will continue to innovate ways to improve the delivery of excellent, high value care. • We will measure successes and failures, and use the results to drive further improvement. • We will be a good neighbor in the communities we serve with donations of time, talent, and capital. • We will be ethical and accountable in all of our decisions and actions.
Peregrine Pharmaceuticals, Inc. (Peregrine) is a clinical-stage biopharmaceutical company that manufactures and develops monoclonal antibodies for the treatment of cancer and viral infections.
Helmer Scientific is an established, entrepreneurial, growth company headquartered in Noblesville, Indiana. We design, integrate, manufacture, market, and distribute specialized medical and laboratory equipment to clinical and life science customers in over 125 countries.